Applied Filters
Eli Lilly secures Alimta patent win over Apotex
Eli Lilly has won a victory in a cancer drug dispute after a federal judge ruled that Canadian pharmaceutical company Apotex’s new drug application infringed the company’s patent.
Sandoz and Momenta to pay $120m to end antitrust suit
Sandoz and Momenta have agreed to pay $120 million to bring an antitrust class action over blockbuster blood clot drug enoxaparin to an end.
Bausch Health resolves patent litigation with Glenmark
Canadian pharmaceutical company Bausch Health and India-based Glenmark Pharmaceuticals have resolved their outstanding IP litigation over Bryhali lotion.
Supermarket chain settles pay-for-delay suit over birth control pill
Dutch supermarket owner Ahold Delhaize has agreed to settle a series of patent infringement suits filed against pharmaceutical companies including Warner Chilcott and Watson over contraceptive pill Loestrin 24 Fe.
Momenta to pay $35m to end enoxaparin class-action suit
Momenta Pharmaceuticals has agreed to pay $35 million to settle a 2015 class-action suit that claimed that it blocked generics of the blockbuster blood clot drug enoxaparin from coming to market.
US senators question ‘national security risks’ posed by Chinese drugs
US senators have requested information regarding the national security risks posed by the role of foreign manufacturing, specifically in China, in the US pharmaceutical products supply chain.
McDonald Hopkins adds new recruit in Chicago
McDonald Hopkins has added Erin Conway as counsel to its IP litigation department in Chicago.
Takeda sues Mylan over gout generic
Takeda has sued Mylan for patent infringement and breach of a licencing agreement over Takeda’s Colcrys drug.
Generic drugmaker to pay $3m antitrust fine
New Jersey-based generic drugmaker Rising Pharmaceuticals has admitted to conspiring to fix prices and allocate customers for a generic hypertension drug.
LSPN Europe: understand our business models, say in-house lawyers
The best lawyers acting for life sciences companies make sure they fully understand their clients’ business models, said in-house counsel at Life Sciences Patent Network 2019.
